Decreased cortical thickness in drug naïve first episode schizophrenia: In relation to serum levels of BDNF

Journal of Psychiatric Research

Volumn 60, Issue , 2015, Pages 22-28

  Song, Xueqin ^a   Quan, Meina ^b   Lv, Luxian ^c   Li, Xue ^a   Pang, Lijuan ^a   Kennedy, David ^b   Hodge, Steven ^b   Harrington, Amy ^b   Ziedonis, Douglas ^b   Fan, Xiaoduo ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

BDNF; Cortical thickness; First episode schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BIOLOGICAL MARKER;

ADULT; AGE; ARTICLE; BRAIN DEVELOPMENT; BRAIN REGION; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICAL THICKNESS (BRAIN); DEVELOPMENTAL DISORDER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HUMAN; INFERIOR PARIETAL LOBULE; INSULA; LEFT HEMISPHERE; LEFT INSULA; MALE; MIDDLE FRONTAL GYRUS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OCCIPITAL GYRUS; RIGHT HEMISPHERE; SCHIZOPHRENIA; SUPERIOR FRONTAL GYRUS; SUPERIOR TEMPORAL GYRUS; SUPRAMARGINAL GYRUS; ADOLESCENT; BLOOD; BRAIN CORTEX; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; YOUNG ADULT;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CEREBRAL CORTEX; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84918800803     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.09.009     Document Type: Article

References (50)

1. Buckley P.F., Mahadik S., Pillai A., Terry A. Neurotrophins and schizophrenia. Schizophr Res 2007, 94:1-11.
2. Cobia D.J., Smith M.J., Wang L., Csernansky J.G. Longitudinal progression of frontal and temporal lobe changes in schizophrenia. Schizophr Res 2012, 139:1-6.
3. Crespo-Facorro B., Kim J., Andreasen N.C., O'Leary D.S., Bockholt H.J., Magnotta V. Insular cortex abnormalities in schizophrenia: a structural magnetic resonance imaging study of first-episode patients. Schizophr Res 2000, 46:35-43.
4. Crespo-Facorro B., Roiz-Santianez R., Perez-Iglesias R., Rodriguez-Sanchez J.M., Mata I., Tordesillas-Gutierrez D., et al. Global and regional cortical thinning in first-episode psychosis patients: relationships with clinical and cognitive features. Psychol Med 2011, 41:1449-1460.
5. Eisenberg D.P., Ianni A.M., Wei S.M., Kohn P.D., Kolachana B., Apud J., et al. Brain-derived neurotrophic factor (BDNF) Val(66)Met polymorphism differentially predicts hippocampal function in medication-free patients with schizophrenia. Mol Psychiatry 2013, 18:713-720.
6. Elvevag B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000, 14:1-21.
7. Erickson K.I., Prakash R.S., Voss M.W., Chaddock L., Heo S., McLaren M., et al. Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume. JNeurosci 2010, 30:5368-5375.
8. Erickson K.I., Prakash R.S., Voss M.W., Chaddock L., Hu L., Morris K.S., et al. Aerobic fitness is associated with hippocampal volume in elderly humans. Hippocampus 2009, 19:1030-1039.
9. Fischl B., Dale A.M. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 2000, 97:11050-11055.
10. Fornito A., Yucel M., Patti J., Wood S.J., Pantelis C. Mapping grey matter reductions in schizophrenia: an anatomical likelihood estimation analysis of voxel-based morphometry studies. Schizophr Res 2009, 108:104-113.
11. Fornito A., Yucel M., Wood S.J., Adamson C., Velakoulis D., Saling M.M., et al. Surface-based morphometry of the anterior cingulate cortex in first episode schizophrenia. Hum Brain Mapp 2008, 29:478-489.
12. Gorski J.A., Zeiler S.R., Tamowski S., Jones K.R. Brain-derived neurotrophic factor is required for the maintenance of cortical dendrites. JNeurosci 2003, 23:6856-6865.
13. Green M.J., Matheson S.L., Shepherd A., Weickert C.S., Carr V.J. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol psychiatry 2011, 16:960-972.
14. Haijma S.V., Van Haren N., Cahn W., Koolschijn P.C., Hulshoff Pol H.E., Kahn R.S. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull 2013, 39:1129-1138.
15. Haller S., Borgwardt S.J., Schindler C., Aston J., Radue E.W., Riecher-Rossler A. Can cortical thickness asymmetry analysis contribute to detection of at-risk mental state and first-episode psychosis? A pilot study. Radiology 2009, 250:212-221.
16. Han X., Jovicich J., Salat D., van der Kouwe A., Quinn B., Czanner S., et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. NeuroImage 2006, 32:180-194.
17. Harrison J.E. Orthodontic Clinical Trials III: reporting of ethical issues associated with clinical trials published in three orthodontic journals between 1989 and 1998. JOrthod 2005, 32:115-121.
18. Hashimoto T., Bergen S.E., Nguyen Q.L., Xu B., Monteggia L.M., Pierri J.N., et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. JNeurosci : Off J Soc Neurosci 2005, 25:372-383.
19. Ho B.C., Andreasen N.C., Dawson J.D., Wassink T.H. Association between brain-derived neurotrophic factor val66met gene polymorphism and progressive brain volume changes in schizophrenia. Am J Psychiatry 2007, 164:1890-1899.
20. Huang E.J., Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001, 24:677-736.
21. Jindal R.D., Pillai A.K., Mahadik S.P., Eklund K., Montrose D.M., Keshavan M.S. Decreased BDNF in patients with antipsychotic naive first episode schizophrenia. Schizophr Res 2010, 119:47-51.
22. Kuperberg G.R., Broome M.R., McGuire P.K., David A.S., Eddy M., Ozawa F., et al. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch Gen Psychiatry 2003, 60:878-888.
23. Lee A.H., Lange C., Ricken R., Hellweg R., Lang U.E. Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. JClin Psychopharmacol 2011, 31:334-336.
24. Levitt J.J., Bobrow L., Lucia D., Srinivasan P. Aselective review of volumetric and morphometric imaging in schizophrenia. Curr Top Behav Neurosci 2010, 4:243-281.
25. Lu B. BDNF and activity-dependent synaptic modulation. Learn Mem 2003, 10:86-98.
26. McCarley R.W., Salisbury D.F., Hirayasu Y., Yurgelun-Todd D.A., Tohen M., Zarate C., et al. Association between smaller left posterior superior temporal gyrus volume on magnetic resonance imaging and smaller left temporal P300 amplitude in first-episode schizophrenia. Arch Gen Psychiatry 2002, 59:321-331.
27. Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998, 37:1553-1561.
28. Qiu A., Gan S.C., Wang Y., Sim K. Amygdala-hippocampal shape and cortical thickness abnormalities in first-episode schizophrenia and mania. Psychol Med 2013, 43:1353-1363.
29. Rais M., Cahn W., Schnack H.G., Hulshoff Pol H.E., Kahn R.S., van Haren N.E. Brain volume reductions in medication-naive patients with schizophrenia in relation to intelligence quotient. Psychol Med 2012, 42:1847-1856.
30. Rizos E., Papathanasiou M.A., Michalopoulou P.G., Laskos E., Mazioti A., Kastania A., et al. Alongitudinal study of alterations of hippocampal volumes and serum BDNF levels in association to atypical antipsychotics in a sample of first-episode patients with schizophrenia. PloS One 2014, 9:e87997.
31. Rizos E.N., Papathanasiou M., Michalopoulou P.G., Mazioti A., Douzenis A., Kastania A., et al. Association of serum BDNF levels with hippocampal volumes in first psychotic episode drug-naive schizophrenic patients. Schizophr Res 2011, 129:201-204.
32. Roiz-Santianez R., Perez-Iglesias R., Quintero C., Tordesillas-Gutierrez D., Mata I., Ayesa R., et al. Insular cortex thinning in first episode schizophrenia patients. Psychiatry Res 2010, 182:216-222.
33. Rosas H.D., Liu A.K., Hersch S., Glessner M., Ferrante R.J., Salat D.H., et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002, 58:695-701.
34. Sartorius A., Hellweg R., Litzke J., Vogt M., Dormann C., Vollmayr B., et al. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009, 42:270-276.
35. Segonne F., Pacheco J., Fischl B. Geometrically accurate topology-correction of cortical surfaces using nonseparating loops. IEEE Trans Med imaging 2007, 26:518-529.
36. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. Areview of MRI findings in schizophrenia. Schizophr Res 2001, 49:1-52.
37. Shepherd A.M., Laurens K.R., Matheson S.L., Carr V.J., Green M.J. Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia. Neurosci Biobehav Rev 2012, 36:1342-1356.
38. Siekmeier P.J., vanMaanen D.P. Development of antipsychotic medications with novel mechanisms of action based on computational modeling of hippocampal neuropathology. PloS One 2013, 8:e58607.
39. Sprooten E., Papmeyer M., Smyth A.M., Vincenz D., Honold S., Conlon G.A., et al. Cortical thickness in first-episode schizophrenia patients and individuals at high familial risk: a cross-sectional comparison. Schizophr Res 2013, 151:259-264.
40. Voineskos A.N., Foussias G., Lerch J., Felsky D., Remington G., Rajji T.K., et al. Neuroimaging evidence for the deficit subtype of schizophrenia. JAMA Psychiatry 2013, 70:472-480.
41. Wakade C.G., Mahadik S.P., Waller J.L., Chiu F.C. Atypical neuroleptics stimulate neurogenesis in adult rat brain. JNeurosci Res 2002, 69:72-79.
42. Webster M.J., Herman M.M., Kleinman J.E., Shannon Weickert C. BDNF and trkB mRNA expression in the hippocampus and temporal cortex during the human lifespan. Gene Expr Patterns 2006, 6:941-951.
43. Weickert C.S., Ligons D.L., Romanczyk T., Ungaro G., Hyde T.M., Herman M.M., et al. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol psychiatry 2005, 10:637-650.
44. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987, 44:660-669.
45. Weinberger D.R. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry what is happening in the schizophrenic brain?. JAMA Psychiatry 2002, 59:553-558.
46. Wiegand L.C., Warfield S.K., Levitt J.J., Hirayasu Y., Salisbury D.F., Heckers S., et al. Prefrontal cortical thickness in first-episode psychosis: a magnetic resonance imaging study. Biol psychiatry 2004, 55:131-140.
47. Wonderlick J.S., Ziegler D.A., Hosseini-Varnamkhasti P., Locascio J.J., Bakkour A., van der Kouwe A., et al. Reliability of MRI-derived cortical and subcortical morphometric measures: effects of pulse sequence, voxel geometry, and parallel imaging. NeuroImage 2009, 44:1324-1333.
48. Xu B., Zang K., Ruff N.L., Zhang Y.A., McConnell S.K., Stryker M.P., et al. Cortical degeneration in the absence of neurotrophin signaling: dendritic retraction and neuronal loss after removal of the receptor TrkB. Neuron 2000, 26:233-245.
49. Zuccato C., Marullo M., Vitali B., Tarditi A., Mariotti C., Valenza M., et al. Brain-derived neurotrophic factor in patients with Huntington's disease. PloS One 2011, 6:e22966.
50. Zugman A., Gadelha A., Assuncao I., Sato J., Ota V.K., Rocha D.L., et al. Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia. Schizophr Res 2013, 148:81-86.